Top news of the week: 16.06.2020.
Finance, Biotechnology, Initial public offering, Medicine, Oncology, Myocardial infarction
Startups
.@DrMichelleBIO in @statnews: "I've always known deep down that the most effective use of my skills is to be an advocate for science and scientists, writ large. That has always been my passion: getting new medicine and new hope to patients." https://t.co/VM2pNzyYyC
OpenA pandemic, a funeral, and a chance to help heal the world
People tend to negotiate with themselves when faced with difficult situations. I did that with the start of the Covid-19 pandemic.
IPO dough! Royalty Pharma CEO is worth $2.2 billion, @nathanvardi writes.
https://t.co/5ItmPIQpKd
OpenMeet The Secretive Wall Street Investor With The Billion Dollar Medicine Cabinet
For 24 years, this former banker quietly purchased small slices of the most expensive and top-selling drugs in the nation and became a billionaire.
After a turbulent few months, Germany takes a stake in COVID-19 vaccine drugmaker CureVac https://t.co/vAbBW6CH8f
OpenAfter a turbulent few months, Germany takes a stake in COVID-19 vaccine drugmaker CureVac
Germany is taking a 23% stake in privately owned CureVac as it preps to push on with work for its mRNA vaccine against the COVID-19 pandemic.
Takeda-partnered Shattuck nabs mighty $118M funding round for immunotherapy, autoimmune work https://t.co/ugPlsG88iy https://t.co/sAExAXoKzO
OpenTakeda-partnered Shattuck nabs mighty $118M funding round for immunotherapy, autoimmune work
After getting off a $46 million series A in 2018, Texas-based biotech Shattuck Labs has followed up with a major $118 million second funding round.
Founded by experts in cardiovascular medicine and human genetics, @VerveTx continues to advance gene editing medicines for heart disease – https://t.co/f08Pf2UNAn
OpenVerve banks $63M to move gene-editing heart attack treatment toward clinic
Verve Therapeutics launched last year with $58.5 million to create a one-and-done treatment to replace the array of drugs we use to treat heart disease. Now, it’s gearing up to move its ...
Investing in the biotech sector
Proud of the past, rooted in the present and optimistic about the future By Geneviève Guertin & Didier Leconte Recently we proudly announced the creation of an important life ...
Verve, raising another $63 million, seeks to advance gene-editing treatment for heart disease
The Cambridge, Mass.-based company, which was officially launched in May 2019, is working on a treatment that would use gene-editing to lower cholesterol.
Sanofi teams up with China biotech Alphamab for breast cancer R&D https://t.co/8VCJAV1uoX https://t.co/mUxQeiL5ho
OpenSanofi teams up with China biotech Alphamab for breast cancer R&D
French Big Pharma Sanofi, looking to bolster its cancer R&D, has penned a new pact with Alphamab Oncology that focuses on HER2-positive breast cancer.